In the PIPELINE
In the PIPELINE
Antibiotic Zyvox (linezolid) by Pharmacia & Upjohn. From oxazolidinone class, aimed at treating active and resistant gram-positive bacteria. Company reports positive Phase II open-label trials on skin and soft tissue infections and community-acquired pneumonia from gram-positives. Oxazlidinone class arrests development of bacteria growth. In trials of 273 patients isolating Staphylococcus aureus, S. epidermidis, S. pyogenes, Enterococcus, long-term follow-up success rates reached 93.2%, Pharmacia reports. Patients were given two or three daily doses of 250 mg, 375 mg or 625 mg. The drug is being formulated in IV, oral, and suspension form. Type II diabetes treatment INS-1, and investigational compound by INSMED Pharmaceuticals. As reported to the American Diabetes Association, compound led to positive results in double-blind, placebo-controlled, randomized one-month Phase II study of 110 patients not already receiving drug treatment. Parameters of glycemic control and lipid profiles improved without inducing weight gain, the company reports. Patients with above-normal lipid profiles showed equal or greater improvement, with reduced plasma triglyceride, LDL cholesterol, and glycemics following an oral glucose load.Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.